MX2012007841A - Derivados de tetrahidropirano contra enfermedades neurologicas. - Google Patents

Derivados de tetrahidropirano contra enfermedades neurologicas.

Info

Publication number
MX2012007841A
MX2012007841A MX2012007841A MX2012007841A MX2012007841A MX 2012007841 A MX2012007841 A MX 2012007841A MX 2012007841 A MX2012007841 A MX 2012007841A MX 2012007841 A MX2012007841 A MX 2012007841A MX 2012007841 A MX2012007841 A MX 2012007841A
Authority
MX
Mexico
Prior art keywords
tetrahydro
derivatives against
pyran derivatives
against neurological
neurological illnesses
Prior art date
Application number
MX2012007841A
Other languages
English (en)
Inventor
Emmanuel Pinard
Sabine Kolczewski
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2012007841A publication Critical patent/MX2012007841A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

La presente invención se refiere a un compuesto de la fórmula general (I) en donde X es -O- o -CH2-; X´ es -O- o -CH2-; con la condición de que uno de X o X´ sea siempre -O- y el otro sea -CH2-. Se ha encontrado que los compuestos de la fórmula general I son buenos inhibidores del transportador de glicina 1 (GlyT-l) y por lo tanto pueden utilizarse para el tratamiento de esquizofrenia, psicosis y otras condiciones neurológicas, incluyendo dolor.
MX2012007841A 2010-02-02 2011-01-28 Derivados de tetrahidropirano contra enfermedades neurologicas. MX2012007841A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10152359 2010-02-02
PCT/EP2011/051179 WO2011095434A1 (en) 2010-02-02 2011-01-28 Tetrahydro-pyran derivatives against neurological illnesses

Publications (1)

Publication Number Publication Date
MX2012007841A true MX2012007841A (es) 2012-07-25

Family

ID=43607732

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012007841A MX2012007841A (es) 2010-02-02 2011-01-28 Derivados de tetrahidropirano contra enfermedades neurologicas.

Country Status (14)

Country Link
US (1) US8524909B2 (es)
EP (1) EP2531190B1 (es)
JP (1) JP5763104B2 (es)
KR (1) KR101467649B1 (es)
CN (1) CN102740848B (es)
AR (1) AR080081A1 (es)
BR (1) BR112012019158A2 (es)
CA (1) CA2785776C (es)
ES (1) ES2511071T3 (es)
HK (1) HK1171189A1 (es)
MX (1) MX2012007841A (es)
RU (1) RU2554344C2 (es)
TW (1) TW201134821A (es)
WO (1) WO2011095434A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
ATE340782T1 (de) * 2003-02-17 2006-10-15 Hoffmann La Roche Piperidinbenzolsulfonamidderivate
DE10315573A1 (de) * 2003-04-05 2004-10-14 Merck Patent Gmbh Substituierte Pyrazole
RU2355690C2 (ru) 2004-01-08 2009-05-20 Ф.Хоффманн-Ля Рош Аг Производные диазаспиропиперидина
EP1796681A2 (en) * 2004-08-02 2007-06-20 Genmedica Therapeutics SL Compounds for inhibiting copper-containing amine oxidases and uses thereof
PE20061156A1 (es) 2004-12-23 2006-12-16 Glaxo Group Ltd Derivados de benzamida como agentes inhibidores del transportador de glicina
US8957063B2 (en) 2008-02-21 2015-02-17 Boehringer Ingelheim International Gmbh Amine and ether compounds which modulate the CB2 receptor

Also Published As

Publication number Publication date
WO2011095434A1 (en) 2011-08-11
RU2554344C2 (ru) 2015-06-27
EP2531190A1 (en) 2012-12-12
JP5763104B2 (ja) 2015-08-12
CA2785776C (en) 2018-04-03
EP2531190B1 (en) 2014-07-23
KR101467649B1 (ko) 2014-12-01
AR080081A1 (es) 2012-03-14
KR20120128652A (ko) 2012-11-27
CN102740848A (zh) 2012-10-17
TW201134821A (en) 2011-10-16
JP2013518844A (ja) 2013-05-23
ES2511071T3 (es) 2014-10-22
US8524909B2 (en) 2013-09-03
US20110190349A1 (en) 2011-08-04
CN102740848B (zh) 2014-08-27
CA2785776A1 (en) 2011-08-11
BR112012019158A2 (pt) 2016-10-04
RU2012136912A (ru) 2014-03-10
HK1171189A1 (en) 2013-03-22

Similar Documents

Publication Publication Date Title
MX2008010931A (es) Quinolonas utiles como inhibidores de sintasa de oxido nitrico inducibles.
MX2009003834A (es) Derivados de pirrolidina como inhibidores de iap.
TN2011000053A1 (en) Organic compounds
TNSN08444A1 (en) Bicyclic derivatives as cetp inhibitors
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
JO3007B1 (ar) مركبات و تركيبات كمثبطات كيناز بروتين
TN2011000291A1 (en) Purine compounds
PH12013500848B1 (en) Trpv1 antagonists and uses thereof
MX2009000884A (es) Derivados de piridizinona.
RS52823B (en) NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
JO2892B1 (en) CYP inhibitors 17
TN2010000293A1 (en) Thiazole derivatives used as pi 3 kinase inhibitors
MY150778A (en) Fused heterocyclic compound
MX2009006630A (es) Derivados de 4-imidazolil-1,2,3,4-tetrahidro-quinola y su uso como inhibidores de aldosterona / 11-beta-hidroxilasa.
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
MX2009009699A (es) Compuestos amino-5-[4-(difluorometoxi)fenil sustituidos]-5-fenilim idazolona como inhibidores de beta-secretasa.
RS53617B1 (en) NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
IL198901A0 (en) Pyrimidine derivatives and multiple myeloma
MX2009007260A (es) Derivados de imidazol como inhibidores de proteina de huso de cinesina (eg-5).
MY147188A (en) Substituted imidazole compounds as ksp inhibitors
JO3067B1 (ar) بيرميدينات بيرازولو امينو كمثبطات ل fak
NO20085317L (no) Imidazoazepinonforbindelser
BRPI0720050A2 (pt) 6-oxo-1,6-diidropirimidin-2-ilas no tratamento de doenças proliferativas
EP2602254A4 (en) HETEROCYCLIC COMPOUND
MX2012000177A (es) 2-carboxamida-cicloamino-ureas sustituidas.

Legal Events

Date Code Title Description
FG Grant or registration